{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:26:56Z","timestamp":1774031216103,"version":"3.50.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ8202"],"award-info":[{"award-number":["2024JJ8202"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of dipeptidyl peptidase 4 (DPP4) inhibitors in treating type 2 diabetes mellitus (T2DM) is increasingly widespread. However, their association with malignancy risk has not been comprehensively evaluated in real-world clinical settings. This study, utilizing the Food and Drug Adverse Event Reporting System (FAERS) database, investigated the potential link between DPP4 inhibitors and malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the FAERS database (January 2019 to December 2024) were analyzed. Descriptive statistics assessed patient demographics for each drug-event combination, while disproportionality analysis based on Reporting Odds Ratio (ROR) and Information Component (IC) metrics valuated cancer-related adverse event (AE) risks. Binary logistic regression was used to minimize potential bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A comprehensive analysis identified 3,764 AE reports linked to malignancies in T2DM individuals treated with DPP4 inhibitors. Signal detection analysis revealed that sitagliptin exhibited the strongest and most extensive positive signals across both the Preferred Terms and Standardized Medical Dictionary for Regulatory Activities Queries. Specifically, significant signals were observed for malignancies (ROR\n                      <jats:sub>025<\/jats:sub>\n                      : 13.80, IC\n                      <jats:sub>025<\/jats:sub>\n                      : 3.48), tumor lysis syndrome (ROR\n                      <jats:sub>025<\/jats:sub>\n                      : 5.79, IC\n                      <jats:sub>025<\/jats:sub>\n                      : 2.32), and site-specific neoplasms (e.g., uterine, fallopian tube, and prostate). Age distribution analysis indicated that the median age of individuals reporting malignancy-related AEs exceeded 70 years in most drug groups. Furthermore, in studies with larger sample sizes, the median time to AE onset for for DPP4 inhibitors ranged from 13 to 15 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates significant associations between all five DPP4 inhibitors and malignancy-related AEs, with sitagliptin showing the highest risk profile. These findings highlight the need for further validation through large-scale prospective studies to verify the observed pharmacovigilance signals and to elucidate their potential clinical significance and underlying biological mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0345281","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:35:13Z","timestamp":1774028113000},"page":"e0345281","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8211-7020","authenticated-orcid":true,"given":"Wan","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gefei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6370-9740","authenticated-orcid":true,"given":"Ji","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"1","key":"pone.0345281.ref001","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12916-024-03483-z","article-title":"Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes","volume":"22","author":"M Sohn","year":"2024","journal-title":"BMC Med"},{"issue":"11","key":"pone.0345281.ref002","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"CF Deacon","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"pone.0345281.ref003","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/dc12-2713","article-title":"A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?","volume":"36","author":"PC Butler","year":"2013","journal-title":"Diabetes Care"},{"key":"pone.0345281.ref004","doi-asserted-by":"crossref","first-page":"154295","DOI":"10.1016\/j.metabol.2020.154295","article-title":"The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes","volume":"109","author":"AP Stoian","year":"2020","journal-title":"Metabolism"},{"issue":"1","key":"pone.0345281.ref005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/1060028015610123","article-title":"Dipeptidyl peptidase-4 inhibitor-associated pancreatic carcinoma: a review of the FAERS database","volume":"50","author":"AK Nagel","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"7","key":"pone.0345281.ref006","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","volume":"62","author":"AE Butler","year":"2013","journal-title":"Diabetes"},{"key":"pone.0345281.ref007","article-title":"Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study","volume":"363","author":"D Abrahami","year":"2018","journal-title":"BMJ"},{"key":"pone.0345281.ref008","doi-asserted-by":"crossref","first-page":"148659","DOI":"10.1016\/j.gene.2024.148659","article-title":"The impacts of dipeptidyl- peptidase 4 (DPP-4) inhibitors on common female malignancies: a systematic review","volume":"927","author":"A Niazmand","year":"2024","journal-title":"Gene"},{"issue":"1","key":"pone.0345281.ref009","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/s41598-017-19055-6","article-title":"Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis","volume":"8","author":"LC Pinto","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"pone.0345281.ref010","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00592-020-01479-8","article-title":"Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials","volume":"57","author":"I Dicembrini","year":"2020","journal-title":"Acta Diabetol"},{"key":"pone.0345281.ref011","doi-asserted-by":"crossref","first-page":"1458500","DOI":"10.3389\/fphar.2024.1458500","article-title":"Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database","volume":"15","author":"W Xiong","year":"2024","journal-title":"Front Pharmacol"},{"issue":"5","key":"pone.0345281.ref012","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2024.07.1456","article-title":"Evaluation of anticancer therapy-related dermatologic adverse events: insights from Food and Drug Administration\u2019s Adverse Event Reporting System dataset","volume":"91","author":"S Salah","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"pone.0345281.ref013"},{"key":"pone.0345281.ref014","doi-asserted-by":"crossref","first-page":"104398","DOI":"10.1016\/j.critrevonc.2024.104398","article-title":"Safety of immune checkpoint inhibitors: an updated comprehensive disproportionality analysis and meta-analysis","volume":"200","author":"S Tyagi","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"pone.0345281.ref015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12916-024-03430-y","article-title":"Diabetes and further risk of cancer: a nationwide population-based study","volume":"22","author":"W-C Chang","year":"2024","journal-title":"BMC Med"},{"key":"pone.0345281.ref016","doi-asserted-by":"crossref","first-page":"108072","DOI":"10.1016\/j.diabres.2020.108072","article-title":"Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"162","author":"R Williams","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"pone.0345281.ref017","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3390\/cancers13092191","article-title":"CD26\/DPP-4: type 2 diabetes drug target with potential influence on cancer biology","volume":"13","author":"E Kawakita","year":"2021","journal-title":"Cancers (Basel)"},{"key":"pone.0345281.ref018","doi-asserted-by":"crossref","first-page":"840142","DOI":"10.3389\/fonc.2022.840142","article-title":"Association between DPP-4 inhibitors and events of colorectal and liver cancers in patients with diabetes receiving second-line agents: a nested case-control study","volume":"12","author":"C-L Chou","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"pone.0345281.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275681","article-title":"Examining the relationship between metformin dose and cancer survival: a SEER-Medicare analysis","volume":"17","author":"L Scarton","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"pone.0345281.ref020","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1742-4658.2009.07526.x","article-title":"The dipeptidyl peptidase IV family in cancer and cell biology","volume":"277","author":"DMT Yu","year":"2010","journal-title":"FEBS J"},{"issue":"21","key":"pone.0345281.ref021","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.3390\/ijms21218110","article-title":"Hypoxia regulates DPP4 expression, proteolytic inactivation, and shedding from ovarian cancer cells","volume":"21","author":"LR Moffitt","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"pone.0345281.ref022","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/0008-5472.CAN-18-0620","article-title":"Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12\/CXCR4\/mTOR axis","volume":"79","author":"F Yang","year":"2019","journal-title":"Cancer Res"},{"issue":"11","key":"pone.0345281.ref023","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12032-020-01419-0","article-title":"The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2\/HO1 pathway","volume":"37","author":"L He","year":"2020","journal-title":"Med Oncol"},{"issue":"11","key":"pone.0345281.ref024","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3390\/ijms18112362","article-title":"ABC Transporters in cancer stem cells: beyond chemoresistance","volume":"18","author":"R-R Begicevic","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"570","key":"pone.0345281.ref025","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau8544","article-title":"Chronic TGF-\u03b2 exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition","volume":"12","author":"Y Katsuno","year":"2019","journal-title":"Sci Signal"},{"issue":"40","key":"pone.0345281.ref026","doi-asserted-by":"crossref","first-page":"30731","DOI":"10.1074\/jbc.M110.128124","article-title":"TNF\u03b1-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines","volume":"285","author":"SY Shin","year":"2010","journal-title":"J Biol Chem"},{"issue":"8","key":"pone.0345281.ref027","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41591-018-0082-y","article-title":"DPP8\/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia","volume":"24","author":"DC Johnson","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"pone.0345281.ref028","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1073\/pnas.0237106100","article-title":"Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice","volume":"100","author":"RW Gelling","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"pone.0345281.ref029","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.cmet.2016.05.017","article-title":"Opposing effects of antidiabetic interventions on malignant growth and metastasis","volume":"23","author":"MH Tsch\u00f6p","year":"2016","journal-title":"Cell Metab"},{"issue":"1","key":"pone.0345281.ref030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcmgh.2018.08.008","article-title":"Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice","volume":"7","author":"S Nishina","year":"2018","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"5","key":"pone.0345281.ref031","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/iub.2454","article-title":"The mechanism of sitagliptin inhibition of colorectal cancer cell lines\u2019 metastatic functionalities","volume":"73","author":"R Varela-Calvi\u00f1o","year":"2021","journal-title":"IUBMB Life"},{"issue":"1","key":"pone.0345281.ref032","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s10194-024-01913-0","article-title":"Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database","volume":"25","author":"W-H Liu","year":"2024","journal-title":"J Headache Pain"},{"key":"pone.0345281.ref033","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.biopha.2018.07.157","article-title":"Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity","volume":"107","author":"B Giri","year":"2018","journal-title":"Biomed Pharmacother"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:35:19Z","timestamp":1774028119000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345281"}},"subtitle":[],"editor":[{"given":"Timotius Ivan","family":"Hariyanto","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0345281","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]}}}